Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Clinical trial NCT06991790 · RECRUITING
Trial details
- NCT number
- NCT06991790
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-05-01
- Primary completion
- 2027-05-01
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.